Tuesday, 19 May | 17:00 – 18:00
TABLE: Virus Detection – New Approaches for Old and New Viruses
Moderator: Andrea Marzi, PhD, Chief, Immunobiology & Molecular Virology Unit, Laboratory of Virology, DIR, NIAID, NIH, United States
- Improved sensitivity of assays for known viruses?
- What samples are the best to look at?
- Newer and faster platforms for virus detection?
- Human versus animal samples – diagnostics versus virus hunt
- Identifying new viruses – assay broadness at the cost of sensitivity and specificity?
TABLE: Developing Point-Of-Care Diagnostics for Antimicrobial Resistance
Moderator: John Hays, PhD, Associate Professor, Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam, The Netherlands
- What is the current state of affairs (laboratory versus POC Testing)?
- AMR diagnostics in HIC versus LMICs?
- How important are diagnostics for AMR in a One Health environment?
- What is the role and success of prizes and national grant funding?
- Test specifications, cost and reimbursement issues
- Other implementation issues
TABLE: The Power of Proteomics in a Post-Genomic World
Moderator: Michael Roehrl, MD, PhD, Associate Professor of Pathology and Laboratory Medicine, Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, United States
- Studying drug interactions in vivo
- A new generation of Precision Clinical Trials (the crucial role of Pathology; optimal specimens for IO trials)
- Multi-omic data in medicine – how do we make it actionable?
Wednesday, 20 May | 11:35 – 12:35
TABLE: Challenges of Commercializing Point-of-Care Diagnostics
Moderator: Oliver Hofmann, PhD, MBA, CEO, SouthWestSensor Limited
- Engineering & upscaling: from academic lab to diagnostic product
- How to select the killer application
- Regulatory and reimbursement – How to navigate through this
- Investment into diagnostics – How to recover from Theranos
TABLE: The Future of Genetic Testing
Moderator Miron Tokarski, CEO, Genomtech S.A.
- The prospects for genetic testing in POC
- Regulatory changes in the EU introduced by IVDR
- The cost-benefit influence of POC genetic testing
- Factors influencing adoption of POC genetic testing in clinical facilities
TABLE: Overcoming the Race to the Bottom: Cost per Test versus Value of Diagnostics
Moderator : Till T. Bachmann, PhD, Reader, Personalised Medicine in Infectious Disease; Deputy Head, Division of Infection and Pathway Medicine, Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, United Kingdom
- Reducing the bill of materials
- Healthcare system drivers
- Challenge of getting health economics data
- Impacts of changing regulatory frameworks
- Behavioural change aspects
TABLE: Exploring Multidimensional Liquid Biopsy Tests
Moderator: Vito Giuseppe D’Agostino, PhD, Group leader, Laboratory of Biotechnology and Nanomedicine, CIBIO, University of Trento, Italy
- Combination of multiple biological sources for liquid biopsy tests
- Create validated platforms making clinicians aware of novel breakthrough technologies
- Creation of networks for paralleling molecular analyses
TABLE: DNA Methylation-Based cfDNA Biomarkers
Moderator: Jason Ross, PhD, Principal Research Scientist, Health and Biosecurity, CSIRO, Australia
- The future of these biomarkers as liquid-biopsy tests for cancer
- What about outside of oncology?
- Bisulfite treatment, it’s the gold standard, but are the emerging alternatives useful for diagnostics?